Celgene Co. (CELG) Position Cut by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its stake in Celgene Co. (NASDAQ:CELG) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,190,020 shares of the biopharmaceutical company’s stock after selling 9,522 shares during the period. New York State Common Retirement Fund owned about 0.28% of Celgene worth $319,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of the company. Thompson Davis & CO. Inc. grew its stake in shares of Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in shares of Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the last quarter. Guidant Wealth Advisors purchased a new position in shares of Celgene in the 3rd quarter valued at approximately $119,000. Motco grew its stake in shares of Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares during the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of Celgene in the second quarter valued at approximately $129,000. 79.71% of the stock is currently owned by institutional investors and hedge funds.

Shares of Celgene Co. (NASDAQ CELG) traded down $0.54 during midday trading on Friday, hitting $99.80. The stock had a trading volume of 5,660,000 shares, compared to its average volume of 7,550,000. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The stock has a market capitalization of $78,570.00, a P/E ratio of 27.65, a price-to-earnings-growth ratio of 0.72 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 64.14% and a net margin of 22.38%. The company had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the prior year, the business earned $1.61 earnings per share. The company’s revenue was up 16.9% compared to the same quarter last year. sell-side analysts expect that Celgene Co. will post 7.68 earnings per share for the current fiscal year.

CELG has been the topic of a number of analyst reports. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Thursday, October 5th. Sanford C. Bernstein cut Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price objective for the company. in a report on Wednesday, December 27th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price objective on shares of Celgene in a report on Monday, October 30th. Finally, Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $130.35.

WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/02/new-york-state-common-retirement-fund-sells-9522-shares-of-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply